Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.77 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.43 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29869055 | 1.00 | MAP4K1 (0.77) | MAP4K1PIK3CGMAP3K11TNIKCYP11B2 | |
| SCHEMBL22922393 | 1.00 | MAP4K1 (0.77) | MAP4K1PIK3CGMAP3K11TNIKCYP11B2 | |
| SCHEMBL29869247 | 1.00 | MAP4K1 (0.77) | MAP4K1PIK3CGMAP3K11TNIKCYP11B2 | |
| SCHEMBL22922488 | 1.00 | MAP4K1 (0.77) | MAP4K1PIK3CGMAP3K11TNIKCYP11B2 | |
| SCHEMBL29869158 | 1.00 | MAP4K1 (0.77) | MAP4K1PIK3CGMAP3K11TNIKCYP11B2 | |
| SCHEMBL22922392 | 1.00 | MAP4K1 (0.77) | MAP4K1PIK3CGMAP3K11TNIKCYP11B2 | |
| SCHEMBL22922484 | 1.00 | MAP4K1 (0.77) | MAP4K1PIK3CGMAP3K11TNIKCYP11B2 | |
| SCHEMBL22922395 | 0.89 | MAP4K1 (0.61) | MAP4K1PIK3CGMAP3K11CYP11B2 | |
| SCHEMBL22922396 | 0.89 | MAP4K1 (0.61) | MAP4K1PIK3CGMAP3K11CYP11B2 | |
| SCHEMBL29869239 | 0.89 | MAP4K1 (0.61) | MAP4K1PIK3CGMAP3K11CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20220267354-A1 | TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267354-A1 | TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | ULK1, SBK1, PHKG1 | MAP4K1 96/4885PIK3CG 1189/4885MAP3K11 68/4885 |
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | ULK1, SBK1, PHKG1 | MAP4K1 96/4885PIK3CG 1189/4885MAP3K11 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.